Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 503-512

  Porcellati, Francesca ^a   Lucidi, Paola ^a   Cioli, Patrizia ^a   Candeloro, Paola ^a   Andreoli, Anna Marinelli ^a   Marzotti, Stefania ^a   Ambrogi, Maura ^a   Bolli, Geremia B ^a   Fanelli, Carmine G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOSE; GLYCEROL; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL;

ADULT; ANAMNESIS; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; EVENING DOSAGE; FEMALE; GAS CHROMATOGRAPHY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INFUSION RATE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LABORATORY TEST; LIPOLYSIS; MALE; MASS SPECTROMETRY; MICROANGIOPATHY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; VASCULAR DISEASE; AGED; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; GLUCOSE CLAMP TECHNIQUE; INJECTION; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED;

AGED; BLOOD GLUCOSE; C-PEPTIDE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN RESISTANCE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 84941113281     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0649     Document Type: Article

References (40)

1. Owens DR, Bolli GB. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008;10:333- 349.
2. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49: 2142-2148.
3. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614-1620.
4. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004;21: 1213-1220.
5. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treatto- Target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080- 3086.
6. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26- week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274.
7. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26: 590-596.
8. European Medicines Agency: Find medicine Human medicine Lantus, insulin glargine. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000284/human-med-000882.jsp&mid=WC0b01ac058001d124. Accessed 1 December 2014.
9. Hamann A, Matthaei S, Rosak C, Silvestre L; HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003;26:1738-1744.
10. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003;26:1490-1496.
11. Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med 2006;23:46-52.
12. Fritsche A, Schweitzer MA, Haring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138: 952-959.
13. Standl E, Maxeiner S, Raptis S, Karimi- Anderesi Z, Schweitzer MA; HOE901/4009 Study Group. Good glycemic control with flexibility in timing of basal insulin supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28: 419-420.
14. Lucidi P, Porcellati F, Rossetti P, et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: A randomized cross-over study. Diabetes Care 2011;34: 1312-1314.
15. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-299.
16. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006;49:1163-1168.
17. Wang Z, Hedrington MS, Gogitidze Joy N, et al. Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care 2010;33: 1555-1560.
18. Jarrett RJ. Rhythms in insulin and glucose. In Endocrine Rhythms. Krieger DT, Ed. New York, Raven, 1979, p. 247-258.
19. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996;45: 1044-1050.
20. Andres R, Swerdoff T, Pozefsky T, Coleman D. Manual feedback technique for the control of blood glucose concentration. In Automation in Analytical Chemistry. Skeggs LT Jr, Ed. New York, Mediad, 1966, p. 486-491.
21. Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-2452.
22. Gastaldelli A, Coggan AR, Wolfe RR. Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. J Appl Physiol (1985) 1999;87:1813-1822.
23. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 1977;26:22-29.
24. Wolfe RR. Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis. New York, Wiley-Liss, 1992, p. 425-426.
25. Radziuk J, Pye S. Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution. Diabetologia 2002;45:1053-1084.
26. Meneghini L, Atkin SL, Gough SC, et al.; NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallelgroup, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858- 864.
27. Gerich JE. Physiology of glucose homeostasis. Diabetes Obes Metab 2000;2: 345-350.
28. Radziuk J, Pye S. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour? Diabetologia 2006;49:1619- 1628.
29. Bolli GB, Gerich JE. The "dawn phenomenon" da common occurrence in both noninsulin- dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984;310:746-750.
30. Porcellati F, Lucidi P, Bolli GB, Fanelli CG. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care 2013;36:3860-3862.
31. Monnier L, Colette C, Dejager S, Owens D. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013; 36:4057-4062.
32. Hatlehol R. Paradoxical rise of the blood sugar concentration in diabetes mellitus. Acta Med Scand Suppl 1924;8:211-266.
33. Izzo JL. Diurnal (24-hour) rhythm in diabetes mellitus; diurnal variations in levels of glucose in blood and urine. Proc Am Diabetes Assoc 1949;9:247-273.
34. Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981;4:579-585.
35. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev 1997;18:716- 738.
36. Staels B. When the clock stops ticking, metabolic syndrome explodes. Nat Med 2006;12: 54-55.
37. Yang X, Downes M, Yu RT, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006;126:801-810.
38. Prasai MJ, George JT, Scott EM. Molecular clocks, type 2 diabetes and cardiovascular disease. Diab Vasc Dis Res 2008;5:89-95.
39. Porcellati F, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 2011;13(Suppl. 1): S15-S24.
40. Heinemann L, Anderson JH Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther 2004;6:698- 718.